Icosabutate Therapy Shows Promising Results in Treating NASH Patients with Type 2 Diabetes: ICONA Study

Date:

Icosabutate Therapy Shows Promising Results in Treating NASH Patients with Type 2 Diabetes: ICONA Study

A recent study conducted by NorthSea Therapeutics B.V. has revealed promising results for the use of Icosabutate therapy in treating non-alcoholic steatohepatitis (NASH) patients with type 2 diabetes (T2D). The study, known as the ICONA study, aimed to assess the safety, tolerability, and efficacy of Icosabutate in NASH patients with fibrosis stages F1-F3.

The study found that patients treated with 600mg of Icosabutate showed a significant increase in the proportion of patients achieving NASH resolution without worsening fibrosis and a ≥2-point decrease in NAS compared to the placebo group (25.8% vs. 11.9%, p=0.03). While the overall study population did not reach statistical significance for the less stringent primary endpoint, the results were highly significant in patients with T2D.

In NASH patients with T2D, the 600mg dose of Icosabutate significantly increased the proportion of patients achieving NASH resolution without worsening fibrosis (35.5% vs. 8.7% placebo, p=0.02) and NASH resolution without worsening fibrosis and a ≥2-point decrease in NAS (35.5% vs. 4.3% placebo, p=0.007). Additionally, a significant improvement in fibrosis stage regression was observed in T2D patients treated with Icosabutate 600mg (31% treatment effect size, p=0.03) using AI technology (qFibrosis, Histoindex).

Based on these highly favorable results in T2D patients, NorthSea Therapeutics plans to pursue the development of Icosabutate as a treatment for NASH patients with T2D. In addition, the company also intends to advance two other clinical Phase 2 SEFA programs, including SEFA-1024 for severe hypertriglyceridemia (SHTG) and SEFA-6179 for the orphan indication IFALD (Intestinal Failure Associated Liver Disease).

See also  OpenAI Set to Launch New AI-Powered Search Engine Challenge Google

The findings from the ICONA phase 2b study will be presented as an oral late-breaker at the AASLD Liver Meeting in Boston on November 13, 2023. The study enrolled 280 patients, with 178 meeting the histologic criteria for inclusion. Patients were randomized to receive once-daily, oral doses of Icosabutate 300mg, Icosabutate 600mg, or placebo for 52 weeks.

Overall, the results of the ICONA study suggest that Icosabutate therapy holds great promise as a potential treatment for NASH patients with type 2 diabetes. Icosabutate’s mechanism of action, which targets FFAR1 and FFAR4, provides a biological rationale for its observed effects in diabetic patients. These findings highlight the need for safe and effective therapies that target both inflammation and fibrosis in NASH patients with T2D.

The positive outcomes seen in this study support further clinical development of Icosabutate and the potential use of FFAR targeting as a therapeutic approach for diabetic NASH. While more research is needed, Icosabutate could potentially serve as a backbone oral therapy for this patient population, addressing the underlying metabolic dysfunction associated with NASH.

NorthSea Therapeutics is a biotech company focused on developing novel strategies for the treatment of NASH and other metabolic diseases. The company is supported by various investors and has licensed the rights to its lead compound, Icosabutate, which has shown positive results in previous clinical trials for hypertriglyceridemia and mixed dyslipidemia.

In conclusion, the ICONA study has demonstrated the potential of Icosabutate therapy in treating NASH patients with type 2 diabetes. The study’s findings highlight the need for new, effective treatments for this patient population and open the door for further development of Icosabutate as a promising therapy for NASH with T2D.

See also  Emerging Technologies and Trends for the Future of Web Development

Frequently Asked Questions (FAQs) Related to the Above News

What is NASH?

NASH stands for non-alcoholic steatohepatitis. It is a progressive liver disease characterized by the accumulation of fat in the liver, along with inflammation and liver cell damage. Unlike alcoholic hepatitis, NASH occurs in individuals who do not consume significant amounts of alcohol.

What is type 2 diabetes (T2D)?

Type 2 diabetes is a chronic condition in which the body becomes resistant to insulin or does not produce enough insulin to regulate blood sugar levels effectively. It is commonly associated with obesity and lifestyle factors, such as poor diet and lack of physical activity.

What is Icosabutate therapy?

Icosabutate therapy is a treatment approach that utilizes a compound called Icosabutate. It is an oral medication that targets FFAR1 and FFAR4, which are receptors involved in regulating inflammation and metabolism. Icosabutate has shown promising results in clinical trials for various metabolic disorders, including NASH and hypertriglyceridemia.

What were the results of the ICONA study?

The ICONA study found that NASH patients with type 2 diabetes who received Icosabutate therapy experienced significant improvements in NASH resolution without worsening fibrosis and a decrease in NAFLD activity score (NAS) compared to the placebo group. These results were highly significant in the group of patients with T2D.

Are there any side effects of Icosabutate therapy?

The ICONA study focused on assessing the safety and tolerability of Icosabutate therapy. While specific details regarding side effects were not mentioned in the news article, it can be inferred that Icosabutate demonstrated a favorable safety profile based on the plans to pursue its development and potential use as a therapy.

What are the next steps for Icosabutate therapy?

Based on the positive results seen in NASH patients with type 2 diabetes, NorthSea Therapeutics plans to further develop Icosabutate as a treatment for this patient population. In addition, the company also intends to advance two other clinical Phase 2 SEFA programs targeting different metabolic disorders.

When will the findings of the ICONA study be presented?

The findings of the ICONA study will be presented as an oral late-breaker at the AASLD Liver Meeting in Boston on November 13, 2023.

Who conducted the ICONA study?

The ICONA study was conducted by NorthSea Therapeutics B.V., a biotech company focused on developing novel strategies for the treatment of NASH and other metabolic diseases.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Elon Musk’s Terrifying Prediction: AI Will Take Over Jobs, Harming Children’s Future

Elon Musk predicts AI will take over jobs, posing a threat to children's future. Are we ready for a world where robots replace humans?

Harvard Graduates Urged to Fight Misinformation by Nobel Peace Prize Winner

Harvard Graduates are urged by a Nobel Peace Prize Winner to combat misinformation in a powerful call to action.

Google’s Alphabet in Talks to Acquire HubSpot for $30 Billion, Boost Cloud Applications Market Competitiveness

Google's Alphabet eyes $30B HubSpot acquisition to boost cloud app market competitiveness against Microsoft.

Groundbreaking Study Reveals 150+ Genetic Variants Linked to Psychiatric Disorders

Groundbreaking study reveals 150+ genetic variants linked to psychiatric disorders using machine learning in human brain cells.